The combination of tucatinib and trastuzumab is also being explored in biliary tract cancers (BTC), where it has shown a cORR of 46.7% in pretreated HER2+ metastatic patients in a phase II trial [47]. Here, ERBB2 is linked to biliary tract neoplasm.